Core Insights - Amazon is investing $50 billion in OpenAI as part of a $110 billion fundraising round, valuing OpenAI at $840 billion, marking a significant move in the AI sector [1][5][7] Group 1: Strategic Positioning - The partnership positions Amazon Web Services (AWS) as a core infrastructure partner for OpenAI, enhancing its competitive stance against Microsoft and Google in the AI landscape [5][8] - Analysts view this investment as a strategic move that keeps Amazon in the AI race, especially after its previous investment in Anthropic, creating a balance against Google [6][10] Group 2: Financial Commitment and Infrastructure - The investment includes an upfront $15 billion, with an additional $35 billion contingent on certain conditions, aimed at co-creating new AI system architecture [7] - OpenAI will expand its existing AWS cloud agreement by $100 billion over 8 years, committing to use 2 gigawatts of AWS Trainium chips [7][14] Group 3: Competitive Dynamics - The partnership raises questions about Amazon's relationship with Anthropic, as the new collaboration with OpenAI introduces competitive tension [10][13] - Amazon's Bedrock platform is expected to benefit from the addition of OpenAI models, potentially making AWS a more attractive option for enterprise AI solutions [11][12] Group 4: Hardware and Custom Silicon Strategy - OpenAI's commitment to deploy 2 gigawatts of Trainium chips serves as a vote of confidence in Amazon's custom silicon strategy, which aims to reduce reliance on Nvidia [14][15] - Increased deployment of Trainium chips is likely to deepen integration between OpenAI's software and AWS infrastructure, securing long-term demand for Amazon's cloud services [15][16]

CRANBROOK, BRITISH COLUMBIA / ACCESS Newswire / March 2, 2026 / Eagle Plains Resources Ltd. (TSX-V:EPL)(OTCQB: EGPLF) ("EPL" or "Eagle Plains") is pleased to announce that partner Refined Energy Corp (CSE:RUU)(OTC:RFMCF)(FRA:CWA0) ("Refined") has commenced a diamond drilling program at Eagle Plains' 100% owned Dufferin West Property, Saskatchewan. ...

Core Insights - Astrana Health, Inc. reported record financial results for the year ended December 31, 2025, with total revenue of $3,181.8 million, a 56% increase year-over-year, and adjusted EBITDA of $205.4 million, up 21% from the previous year [1][2][5] - The company anticipates approximately 24% revenue growth and 29% adjusted EBITDA growth for 2026, driven by the integration of Prospect Health [1][2] Financial Highlights for Year Ended December 31, 2025 - Adjusted EPS - diluted of $2.20 [1] - Adjusted EBITDA of $205.4 million, up from $170.4 million [1] - Total revenue of $3,181.8 million, up from $2,034.5 million [1] - Net income attributable to Astrana of $22.5 million [1] Financial Highlights for Fourth Quarter 2025 - Total revenue of $950.5 million, a 43% increase from $665.2 million [1] - Adjusted EBITDA of $52.5 million, up 50% from $35.0 million [1] - Net income attributable to Astrana of $6.0 million [1] Segment Results for Year Ended December 31, 2025 - Care Partners revenue of $3,022.6 million, up 55% from $1,949.0 million [1] - Care Delivery revenue of $250.7 million, up 83% [2] - Care Enablement revenue of $246.7 million, up 59% [2] Update on Annual Report Filing - The company plans to file a Form 12b-25 to extend the deadline for its Annual Report on Form 10-K due to a material weakness in internal control over financial reporting [1][2] Stock Repurchase Program - The Board of Directors increased the share repurchase program from $50 million to $100 million, with $35.9 million remaining available as of December 31, 2025 [1][2] 2026 Guidance - For the three months ending March 31, 2026, total revenue is expected to be between $900 million and $1,000 million, and adjusted EBITDA between $60 million and $70 million [2][5] - For the year ending December 31, 2026, total revenue guidance is between $3,800 million and $4,100 million, and adjusted EBITDA between $250 million and $280 million [2][5]

Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors [Accessibility Statement] Skip NavigationGRAND RAPIDS, Mich., March 2, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the appointment of Drew Hykes to the company's Board of Directors ("Board") and as a member of the Compensation Committee, effective February 26 ...

igsh=MW9jY3g0MmZiaG5pNg%3D%3D&utm_source=qr#]Follow us on YouTube: [https://www.youtube.com/@GreenRainEnergy]Forward Looking Statements:This release contains forward- looking statements under Sections 27A and 21E of U.S. securities laws, subject to safe harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially, including technical, permitting, or other challenges. Green Rain Energy assumes no obligation to update forward-looking statements excep ...

results to differ materially from those in the forward-looking statements include (1) the timing and extent of changes in raw material and component prices, (2) the effects of fluctuations in the commercial/industrial new construction market, (3) the timing and extent of changes in interest rates, as well as other competitive factors during the year, and (4) general economic, market or business conditions. For a discussion of such risks and uncertainties, which could cause actual results to differ from thos ...

Prepares for fully funded, 5,000 m drill program, testing new targets WHITE ROCK, BC / ACCESS Newswire / March 2, 2026 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena" or the "Company") is pleased to announce the receipt of permits (PR 25 00201) for its upcoming maiden drill program at its flagship Laird Lake project, located in Ontario's world-class Red Lake Gold District. With receipts in hand, drill contractors selected, and targets further refined (including new geophysical interpretations), ...

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, exp ...

Thomson Reuters Announces Planned CFO Transition [Accessibility Statement] Skip NavigationTORONTO, March 2, 2026 /PRNewswire/ -- Thomson Reuters (TSX/Nasdaq: TRI), a global content and technology company, today announced that Mike Eastwood, Chief Financial Officer, will retire from the role following a planned transition. Mr. Eastwood will become Chairman of the Board of the Thomson Reuters Foundation, succeeding Jim Smith, who previously served as President and CEO of Thomson Reuters. Mr. Eastwood will als ...

HOLON, ISRAEL, March 2, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results for the fourth quarter and full year 2025 and provided a corporate update. Dr. Ophir continued, "Across our pipeline, we continue to execute with discipline. In 2025, we initiated dosing in new clinical trials of COM701 MAIA-ovarian and of GS-0321 Phase 1 and expanded our clinica ...